QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia and Glycaemic Variability Determined by Simultaneous Ambulatory Monitoring
This study, sponsored by the Royal Prince Alfred Hospital in Sydney, Australia, investigates the relationship between hypoglycaemia and QT interval abnormalities in patients with Type 2 Diabetes Mellitus (T2DM) treated with sulfonylureas. Given the increasing focus on cardiovascular safety in diabetes treatments, particularly in light of findings from major trials (ACCORD, ADVANCE, VADT), this research addresses a critical area of concern for both clinicians and pharmaceutical companies. The results may influence treatment guidelines and the development of new therapies, potentially impacting market dynamics for diabetes medications, especially sulfonylureas. Companies involved in diabetes care should monitor these findings closely for implications on product safety profiles and market positioning.
Indication: Diabetes Related Complications
Modality: medical device
Target: QT Interval Prolongation and Glycaemic Variability in Type 2 Diabetes Patients Treated with Sulfonylureas
Sponsor: Royal Prince Alfred Hospital, Sydney, Australia
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: QT Interval Prolongation and Glycaemic Variability in Type 2 Diabetes Patients Treated with Sulfonylureas
View original source fields
Condition raw: Diabetes Related Complications
Condition normalized: Diabetes Related Complications
Modality raw: medical device
Modality normalized: medical device
Target raw: QT Interval Prolongation and Glycaemic Variability in Type 2 Diabetes Patients Treated with Sulfonylureas
Target normalized: QT Interval Prolongation and Glycaemic Variability in Type 2 Diabetes Patients Treated with Sulfonylureas